India Proposes Expansion of Import Gateways for Drugs and Medical Devices

Context

The Union Health Ministry has proposed expanding authorised entry points for importing drugs, medical devices and cosmetics into India through a draft amendment to Rule 43A of the Drugs Rules, 1945. Objections and suggestions can be submitted within 30 days from 2 November 2026.

About Rule 43A and the Proposal

1. Rule 43A Provision: Mandates specific ports, airports, railway stations, and land borders through which drugs, medical devices, and cosmetics can enter India, with regulatory clearance handled by CDSCO (Central Drugs Standard Control Organisation) offices at these gateways.
2. Proposed Additions: Adds 10 new inland and air entry points across 5 states:

• Haryana: ICDs (Inland Container Depots) at Sonipat, Piyala, and Harsaru.
• Uttar Pradesh: ICD Dadri and Noida International Airport.
• Gujarat: ICD Gandhidham/Mundra.
• Telangana: ICDs at Sanath Nagar and Thimmapur (Hyderabad).
• Karnataka: ICD Whitefield (Bengaluru) and SEZ (Special Economic Zone) Bommasandra.

1. Role of ICDs: Functions as an inland customs clearance and storage hub for containerized cargo, decoupling regulatory clearances from congested coastal seaports.
2. Recent Expansions: Follows earlier inclusion of ICD Dhannad and ICD Tihi in Madhya Pradesh.
3. Approval Process: Issued by the Health Ministry after consulting DTAB (Drugs Technical Advisory Board), awaiting public feedback before finalization.

Rationale for Rule 43A Amendment

1. Decongesting Major Ports: Reduces regulatory delays and cargo load at congested coastal ports like JNPT (Jawaharlal Nehru Port Trust).
2. Improved Regional Connectivity: Gives direct import clearance to inland hubs in Haryana, Uttar Pradesh, Telangana, and Karnataka.
3. Lower Logistics Costs: Reduces inland transport and holding costs, leading to faster delivery of drugs and medical devices.
4. Cold-Chain & Air Cargo Support: Noida International Airport acts as a strategic northern hub for time-sensitive, temperature-controlled pharma imports.

India’s Pharmaceutical Sector

1. Global Position: Ranks 3rd globally by volume and 11th by value.
2. Manufacturing Base: Includes over 3,000 companies and 10,500 units, contributing ~8% of global API (Active Pharmaceutical Ingredient)
   • API (Active Pharmaceutical Ingredient): The primary biologically active component in a drug responsible for its health effect (e.g., paracetamol in Crocin).
3. Generic Medicines Dominance: Supplies ~20% of global generic medicine demand (drugs with identical active ingredients to branded versions, but at lower costs).
4. Vaccine Manufacturing: Produces ~60% of global vaccines by volume, led by producers like the Serum Institute of India (Pune).
5. Export & Market Size: Exported USD 30.5 billion (2024–25) across 191 countries (~50% to strict markets like the US/Europe); domestic market targeted to grow from USD 60 billion to USD 130 billion by 2030.

Policy Support & Ecosystem for India’s Pharma Sector

1. Biopharma SHAKTI (Union Budget 2026–27): A ₹10,000 crore, five-year scheme to establish India as a global hub for biologics and biosimilars:

• Biologics: Complex medicines derived from living organisms (e.g., vaccines, monoclonal antibodies).
• Biosimilars: Highly similar, affordable versions of original approved biologics.
• Core Focus: Enhances clinical trial capacity, research facilities, and upgrades NIPERs (National Institutes of Pharmaceutical Education and Research).

1. FDI (Foreign Direct Investment) Rules: Permits 100% FDI across the sector — Greenfield (new facilities) is 100% via the automatic route, while Brownfield (existing units) allows up to 74% via automatic route (government approval needed beyond 74%).
2. Supply-Chain Infrastructure: Boosted by PLI (Production Linked Incentive) schemes for bulk drugs and formulations, 3 Bulk Drug Parks, and the PRIP (Promotion of Research and Innovation in Pharma) scheme.
3. Affordable Generic Medicine Access: Operates 18,646 Jan Aushadhi Kendras (March 2026) to provide low-cost generics, targeting 25,000 Kendras by March 2027.
4. MSME Technology Upgrade: RPTUAS (Revamped Pharmaceutical Technology Upgradation Assistance Scheme) provides financial aid to small pharma companies to meet Revised Schedule-M and WHO-GMP (Good Manufacturing Practices) quality standards.

Key Challenges

1. Import Dependence on APIs: India relies on China for ~70% of API (Active Pharmaceutical Ingredient) imports, making domestic supply chains vulnerable to global shocks and price fluctuations.
2. Low R&D Spending: Domestic pharma firms invest only 7–8% of revenue in R&D (Research and Development), lagging behind global innovators (15–25%).
3. Quality & Compliance Costs: Transitioning to revised Schedule M — WHO-GMP (Good Manufacturing Practices) requires heavy capital investment, burdening MSMEs (Micro, Small and Medium Enterprises).
4. Drug Price Controls: Strict regulation under NLEM (National List of Essential Medicines) and NPPA (National Pharmaceutical Pricing Authority) keeps drugs affordable but squeezes industry profit margins and reinvestment.
5. Global Regulatory Standards: Meeting varied, strict compliance requirements from foreign regulators (e.g., US FDA, EMA, UK MHRA).
6. High Out-of-Pocket Spending: Direct household health spending accounts for ~40% of total health expenditure, causing high financial strain.

Way Forward

1. Focus on Biologics & Biosimilars: Expand biomanufacturing capabilities for advanced therapies like monoclonal antibodies and gene therapy.
2. Reduce API Import Reliance: Boost domestic production of APIs and KSMs (Key Starting Materials) using PLI (Production Linked Incentive) schemes and Bulk Drug Parks.
3. Increase R&D Investment: Spur public-private R&D spending and strengthen industry–academia partnerships.
4. Enforce Quality Standards: Ensure seamless compliance with revised Schedule M to align domestic manufacturing with global WHO-GMP standards.
5. Shift to High-Value Exports: Scale up CDMOs (Contract Development and Manufacturing Organisations) to move from basic generics to complex formulations.
6. Improve Import Logistics: Equip new entry points with dedicated CDSCO (Central Drugs Standard Control Organisation) staff and testing labs for faster clearances.

FAQs

Q1. What is an ICD?
Ans. An Inland Container Depot is an inland facility for customs clearance and storage of containers.

Q2. What is an API?
Ans. An Active Pharmaceutical Ingredient is the main component of a medicine responsible for its therapeutic effect.

Q3. What is Biopharma SHAKTI?
Ans. A ₹10,000 crore initiative under Budget 2026–27 to strengthen India’s biologics and biosimilars industry.

Q4. How do generics help affordability?
Ans. They provide the same therapeutic benefits as branded drugs at lower prices, generally after patent expiry.